Empagliflozin

  • Chemical Properties
CAS No. 864070-44-0 Cat. No. BCP06962
Name Empagliflozin
Synonyms BI 10773; BI10773; BI-10773; CE0108; CS0940; PB23119; VA10802; AJ93046;
Formula C23H27ClO7 M. Wt 450.91
  • Biological Activity
Description Empagliflozin is an orally available competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2; SLC5A2) with antihyperglycemic activity. Upon oral administration, empagliflozin selectively and potently inhibits SGLT2 in the kidneys, thereby suppressing the reabsorption of glucose in the proximal tubule. Inhibition of SGLT2 increases urinary glucose excretion by the kidneys, resulting in a reduction of plasma glucose levels in an insulin-independent manner. Inhibition of SGLT2 in the kidneys also suppresses the renal reabsorption of 1,5-anhydroglucitol (1,5AG). This lowers serum 1,5AG and neutrophil 1,5-anhydroglucitol-6-phosphate (1,5AG6P) levels, which may improve neutropenia and neutrophil dysfunction in patients with glycogen storage disease type Ib (GSD Ib). SGLT2, a transport protein exclusively expressed in the proximal renal tubules, mediates approximately 90% of renal glucose reabsorption from tubular fluid.
Pathways Ion Channel/Membrane Transporter GPCR/G Protein 
Targets SGLT 

Structure

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
Service & Tech Support:orders@biochempartner.com
Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.